Advertisement

Pharmacy

Drugstore chain Rite Aid may be delisted from the New York Stock Exchange as its share price sinks below $1, according to CNBC.

After a slower year of merger and acquisition activity than expected in 2018, 2019 started off with a bang when Bristol-Myers Squibb agreed to buy Celgene for $74 billion in cash and stock — one of the largest deals in…

Advertisement

Bristol-Myers Squibb plans to acquire cancer drugmaker Celgene for $74 billion in cash and stock — one of the largest deals in pharmaceutical history.

Advertisement